<DOC>
	<DOCNO>NCT00358683</DOCNO>
	<brief_summary>The primary aim study allow patient suffer Crohn 's disease , complete therapeutic confirmatory study C87055 certolizumab pegol benefit treatment , receive treatment certolizumab pegol drug available Crohn 's disease indication Greece .</brief_summary>
	<brief_title>A Trial Evaluating Safety Chronic Therapy With Certolizumab Pegol Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Crohn 's disease diagnosis Patients complete treatment period study C87055 ( previously treat infliximab ) benefit study treatment , per investigatior 's discretion . Subject withdrawn prematurely C87055 study . Subject receive treatment certolizumab pegol medication permit C87055 study . Female patient childbearing age NOT practicing ( Investigator 's opinion ) effective birth control . All female patient must test negative serum pregnancy test study entry negative urine test immediately every certolizumab pegol administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>certolizunab pegol</keyword>
	<keyword>long term safety follow-up</keyword>
	<keyword>Chrohn 's disease</keyword>
	<keyword>infliximab failure patient</keyword>
	<keyword>Greek population</keyword>
</DOC>